KalVista Pharmaceuticals (NASDAQ:KALV) Given Buy Rating at Needham & Company LLC

KalVista Pharmaceuticals (NASDAQ:KALV)‘s stock had its “buy” rating reaffirmed by analysts at Needham & Company LLC in a report issued on Wednesday,Benzinga reports. They currently have a $28.00 price objective on the specialty pharmaceutical company’s stock. Needham & Company LLC’s price target indicates a potential upside of 131.94% from the stock’s current price.

Several other research analysts also recently commented on the stock. JMP Securities began coverage on shares of KalVista Pharmaceuticals in a research report on Friday, January 31st. They set an “outperform” rating and a $19.00 price objective for the company. HC Wainwright reiterated a “buy” rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a research note on Friday, March 14th. Bank of America initiated coverage on KalVista Pharmaceuticals in a research report on Wednesday, December 18th. They set a “buy” rating and a $22.00 price objective for the company. Jones Trading reiterated a “buy” rating and issued a $30.00 target price on shares of KalVista Pharmaceuticals in a research report on Wednesday. Finally, TD Cowen began coverage on KalVista Pharmaceuticals in a research note on Tuesday, January 7th. They set a “buy” rating and a $30.00 target price for the company. Seven research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, KalVista Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $24.83.

KalVista Pharmaceuticals Trading Down 3.4 %

KalVista Pharmaceuticals stock traded down $0.43 during trading hours on Wednesday, reaching $12.07. 72,153 shares of the stock were exchanged, compared to its average volume of 385,613. KalVista Pharmaceuticals has a twelve month low of $7.30 and a twelve month high of $15.50. The company has a market cap of $600.17 million, a P/E ratio of -3.32 and a beta of 0.76. The stock has a 50 day moving average of $10.32 and a two-hundred day moving average of $10.23.

Insider Buying and Selling at KalVista Pharmaceuticals

In other KalVista Pharmaceuticals news, major shareholder Venrock Healthcare Capital Par bought 43,707 shares of KalVista Pharmaceuticals stock in a transaction on Thursday, January 30th. The shares were purchased at an average cost of $8.76 per share, with a total value of $382,873.32. Following the acquisition, the insider now directly owns 4,986,480 shares of the company’s stock, valued at $43,681,564.80. The trade was a 0.88 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Benjamin L. Palleiko sold 6,669 shares of the firm’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $11.97, for a total transaction of $79,827.93. Following the transaction, the chief executive officer now directly owns 287,811 shares of the company’s stock, valued at $3,445,097.67. The trade was a 2.26 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders bought 236,055 shares of company stock worth $2,162,146 and sold 17,292 shares worth $184,625. Corporate insiders own 10.50% of the company’s stock.

Institutional Trading of KalVista Pharmaceuticals

A number of institutional investors and hedge funds have recently bought and sold shares of KALV. State Street Corp increased its stake in shares of KalVista Pharmaceuticals by 68.1% in the third quarter. State Street Corp now owns 1,271,609 shares of the specialty pharmaceutical company’s stock valued at $14,725,000 after buying an additional 515,179 shares during the period. Hennion & Walsh Asset Management Inc. acquired a new stake in KalVista Pharmaceuticals during the 4th quarter valued at approximately $634,000. Vestal Point Capital LP raised its holdings in KalVista Pharmaceuticals by 73.9% during the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the specialty pharmaceutical company’s stock worth $46,320,000 after purchasing an additional 1,700,000 shares during the last quarter. Barclays PLC raised its holdings in KalVista Pharmaceuticals by 418.5% during the 3rd quarter. Barclays PLC now owns 67,222 shares of the specialty pharmaceutical company’s stock worth $778,000 after purchasing an additional 54,257 shares during the last quarter. Finally, Readystate Asset Management LP acquired a new position in shares of KalVista Pharmaceuticals in the 3rd quarter worth approximately $2,084,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).